Early Plasma Circulating Tumor DNA as a Potential Biomarker of Disease Recurrence in Non-metastatic Prostate Cancer
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose In non-metastatic prostate cancer (nmPCa) setting, it is important to early identify the patients at risk of biochemical recurrence (BCR) for immediate postoperative intervention. Our study aimed to evaluate the potential clinical utility of circulating tumor DNA (ctDNA) for predicting disease recurrence.Materials and Methods This real-world observational study evaluated 161 cases of nmPCa undergoing next-generation sequencing at our institution. A total of 139 ctDNA samples and 31 biopsied tumor tissue underwent genomic profiling. The study endpoint was BCR after radical prostatectomy. Relationships between the ctDNA status and the biochemical progression-free survival (bPFS) were analyzed by log-rank test and multivariate Cox regression.Results Of 161 enrolled patients, 19 (11.8%) harbored deleterious alterations in <i>NCOR2</i>, followed by <i>BRCA2</i> (3.7%), <i>ATR</i> (2.5%), and <i>CDK12</i> (2.5%). Of available pre-operative blood samples (n=139), ctDNA was detectable in 91 (65.5%). Until last follow-up, 56 of 68 patients (85.3%) with detectable ctDNA had achieved BCR, whereas only eight of 39 patients (20.5%) with undetectable ctDNA had achieved BCR. Patients who had undetectable ctDNA experienced significantly longer bPFS compared with those who had detectable ctDNA (not available vs. 8.2 months; hazard ratio, 0.14; p < 0.01). Pre-operative ctDNA status was a significant prognostic factor of disease recurrence.Conclusion Pre-operative ctDNA detection could identify patients at high risk of recurrence and has the potential to inform immediate postoperative interventions, but these approaches remain to be validated in prospective studies. ctDNA studies can provide insights into accurate monitoring and precise treatment rather than simply following routine clinical care.
Abstract
Purpose In non-metastatic prostate cancer (nmPCa) setting, it is important to early identify the patients at risk of biochemical recurrence (BCR) for immediate postoperative intervention. Our study aimed to evaluate the potential clinical utility of circulating tumor DNA (ctDNA) for predicting disease recurrence.Materials and Methods This real-world observational study evaluated 161 cases of nmPCa undergoing next-generation sequencing at our institution. A total of 139 ctDNA samples and 31 biopsied tumor tissue underwent genomic profiling. The study endpoint was BCR after radical prostatectomy. Relationships between the ctDNA status and the biochemical progression-free survival (bPFS) were analyzed by log-rank test and multivariate Cox regression.Results Of 161 enrolled patients, 19 (11.8%) harbored deleterious alterations in <i>NCOR2</i>, followed by <i>BRCA2</i> (3.7%), <i>ATR</i> (2.5%), and <i>CDK12</i> (2.5%). Of available pre-operative blood samples (n=139), ctDNA was detectable in 91 (65.5%). Until last follow-up, 56 of 68 patients (85.3%) with detectable ctDNA had achieved BCR, whereas only eight of 39 patients (20.5%) with undetectable ctDNA had achieved BCR. Patients who had undetectable ctDNA experienced significantly longer bPFS compared with those who had detectable ctDNA (not available vs. 8.2 months; hazard ratio, 0.14; p < 0.01). Pre-operative ctDNA status was a significant prognostic factor of disease recurrence.Conclusion Pre-operative ctDNA detection could identify patients at high risk of recurrence and has the potential to inform immediate postoperative interventions, but these approaches remain to be validated in prospective studies. ctDNA studies can provide insights into accurate monitoring and precise treatment rather than simply following routine clinical care.
참고문헌 (29)
- Siegel RL, "Cancer statistics, 2020", CA Cancer J Clin, 70, pp.7~30 (2020)
- Zhu Y, "Epidemiology and genomics of prostate cancer in Asian men", Nat Rev Urol, 18, pp.282~301 (2021)
- Allemani C, "Global surveillance of trends in cancer survival 2000-14(CONCORD-3) : analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries", Lancet, 391, pp.1023~1075 (2018)
- Mottet N, "EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1 : screening, diagnosis, and local treatment with curative intent", Eur Urol, 71, pp.618~629 (2017)
- van der Toom EE, "Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies", Nat Rev Urol, 16, pp.7~22 (2019)
- Han M, "Biochemical(prostate specific antigen)recurrence probability following radical prostatectomy for clinically localized prostate cancer", J Urol, 169, pp.517~523 (2003)
- Diehl F, "Circulating mutant DNA to assess tumor dynamics", Nat Med, 14, pp.985~990 (2008)
- Vandekerkhove G, "Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer", Eur Urol, 75, pp.667~675 (2019)
- Bettegowda C, "Detection of circulating tumor DNA in early-and late-stage human malignancies", Sci Transl Med, 6, pp.224ra24~ (2014)
- Lee B, "Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer", Ann Oncol, 30, pp.1472~1478 (2019)
- Magbanua MJM, "Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival", Ann Oncol, 32, pp.229~239 (2021)
- Sumanasuriya S, "Elucidating prostate cancer behaviour during treatment via low-pass whole-genome sequencing of circulating tumour DNA", Eur Urol, 80, pp.243~253 (2021)
- Raja R, "Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab", Clin Cancer Res, 24, pp.6212~6222 (2018)
- Yang J, "Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer", Cell Death Dis, 11, pp.346~ (2020)
- Tie J, "Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer : a prospective biomarker study", Gut, 68, pp.663~671 (2019)
- Tie J, "Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer", Sci Transl Med, 8, pp.346ra92~ (2016)
- Garcia-Murillas I, "Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer", Sci Transl Med, 7, pp.302ra133~ (2015)
- Dong B, "Use of circulating tumor DNA for the clinical management of metastatic castration-resistant prostate cancer : a multicenter, real-world study", J Natl Compr Canc Netw, 19, pp.905~914 (2021)
- Vandekerkhove G, "Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer", Clin Cancer Res, 23, pp.6487~6497 (2017)
- Fan L, "Comparative analysis of genomic alterations across castration sensitive and castration resistant prostate cancer via circulating tumor DNA sequencing", J Urol, 205, pp.461~469 (2021)
- Cancer Genome Atlas Research Network, "The molecular taxonomy of primary prostate cancer", Cell, 163, pp.1011~1025 (2015)
- Hennigan ST, "Low abundance of circulating tumor DNA in localized prostate cancer", JCO Precis Oncol, 3 (2019)
- Chen E, "Cell-free DNA detection of tumor mutations in heterogeneous, localized prostate cancer via targeted, multiregion sequencing", JCO Precis Oncol, 5 (2021)
- Li J, "A genomic and epigenomic atlas of prostate cancer in Asian populations", Nature, 580, pp.93~99 (2020)
- Fraser M, "Genomic hallmarks of localized, non-indolent prostate cancer", Nature, 541, pp.359~364 (2017)
- Jamaspishvili T, "Clinical implications of PTEN loss in prostate cancer", Nat Rev Urol, 15, pp.222~234 (2018)
- Lau E, "Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression", Genome Med, 12, pp.72~ (2020)
- Chen K, "Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer(DYNAMIC)", Clin Cancer Res, 25, pp.7058~7067 (2019)
- Tan L, "Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA", Ann Oncol, 30, pp.804~814 (2019)